Technological innovation in diagnostic imaging is a key driver of growth in the Dry Age-Related Macular Degeneration Market. Devices such as spectral-domain optical coherence tomography (SD-OCT) and ultra-widefield imaging have enhanced the ability of ophthalmologists to detect and monitor dry AMD progression with unprecedented precision. These technologies facilitate earlier diagnosis, allowing for timely intervention that can slow vision loss and improve patient quality of life.
Moreover, advancements in artificial intelligence (AI) are beginning to play a vital role in AMD diagnosis and prognosis. AI-powered software can analyze retinal images to identify subtle changes that might be missed by the human eye, enabling more accurate risk assessments. This integration of AI in diagnostics is expected to drive adoption of cutting-edge tools and expand the Dry Age-Related Macular Degeneration Market substantially in the coming years.